Mar. 5 at 12:34 PM
$MIRA is sitting on a cluster of near-term catalysts—Phase 1 completion for Ketamir-2, a fresh analyst target of
$8, and a shrinking short float—that could spark a meaningful upside move. Phase 1 dosing is finished with no serious safety issues.• MIRA enrolled 56 healthy volunteers and reported “no serious adverse events or dose-limiting toxicities,” clearing the path for Phase 2a filing in H1 2026 1.
